However, these are in line with our findings, which show that intermediate TMB in NTRK1 causes low levels of tumor infiltration of immune cells, notably CD8+ T cells, and the role of CD8+ T cells is more established over other immune cells in the killing of cancerous cells and is used in cancer immunotherapy [79]. This evidence concerns the gene CD8A and neoplasm.